THYROID GLAND ANAPLASTIC CARCINOMA
Clinical trials for THYROID GLAND ANAPLASTIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new THYROID GLAND ANAPLASTIC CARCINOMA trials appear
Sign up with your email to follow new studies for THYROID GLAND ANAPLASTIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shrinks thyroid tumors before surgery in early trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib given before surgery in 30 people with thyroid cancer that has a specific genetic change (RET alteration). The goal is to see if the drug can shrink tumors and make surgery more successful. Participants take selpercatinib for a shor…
Matched conditions: THYROID GLAND ANAPLASTIC CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:46 UTC
-
New drug cocktail shows promise against deadly thyroid cancer before surgery
Disease control OngoingThis study tests whether giving three drugs (pembrolizumab, dabrafenib, and trametinib) before surgery can help control a rare and aggressive thyroid cancer called anaplastic thyroid cancer with a BRAF mutation. About 30 adults will receive the drug combination, then undergo surg…
Matched conditions: THYROID GLAND ANAPLASTIC CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:44 UTC
-
Your own tumor cells could fight your cancer: new trial tests personalized T-Cell therapy
Disease control OngoingThis phase 2 trial tests a personalized cell therapy called LN-145 for people with certain advanced cancers (like ovarian, breast, thyroid, or bone cancers) that have not responded to treatment or have returned. The therapy uses a patient's own immune cells, taken from their tumo…
Matched conditions: THYROID GLAND ANAPLASTIC CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Promising combo therapy targets deadly thyroid cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with aggressive thyroid cancers (anaplastic or poorly differentiated) live longer. About 50 adults with advanced or inoperable cancer will receive different drug combinati…
Matched conditions: THYROID GLAND ANAPLASTIC CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC